NCT06976892 - Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions

High Grade Serous Ovarian Cancer

Interventions

DRUG

Dose Level 2 (starting dose)

Idetrexed: 9 mg/m2 I.V. (days 1 \& 8) Olaparib: 300 mg P.O. (days1-7, 15-21)

DRUG

Dose Level 1

Idetrexed: 9 mg/m2 I.V. (days 1 \& 8) Olaparib: 200 mg P.O. (days1-7, 15-21)

DRUG

Dose Level -1

Idetrexed: 9 mg/m2 I.V. (days 1 \& 8) Olaparib: 150 mg P.O. (days1-7, 15-21)

DRUG

Dose Level 3

Idetrexed: 12 mg/m2 I.V. (days 1 \& 8) Olaparib: 200 mg P.O. (days1-7, 15-21)

DRUG

Maximum Tolerated Dose

MTD of Olaparib in combination with idetrexed established from Dose Escalation

Trial Locations (3)

NOT_YET_RECRUITING

Addenbrooke's Hospital, Cambridge

NOT_YET_RECRUITING

Velindre Cancer Centre, Cardiff

RECRUITING

Royal Marsden Hospital - Drug Development Unit, Sutton